Compare MLM & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLM | ALNY |
|---|---|---|
| Founded | 1993 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.6B | 60.1B |
| IPO Year | 1994 | 2004 |
| Metric | MLM | ALNY |
|---|---|---|
| Price | $629.17 | $394.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 27 |
| Target Price | ★ $648.38 | $484.39 |
| AVG Volume (30 Days) | 386.1K | ★ 1.1M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 18.97 | 0.33 |
| Revenue | ★ $6,903,000,000.00 | $3,210,070,000.00 |
| Revenue This Year | $1.41 | $69.60 |
| Revenue Next Year | $8.49 | $42.67 |
| P/E Ratio | ★ $33.13 | $1,205.23 |
| Revenue Growth | 17.84 | ★ 53.24 |
| 52 Week Low | $441.95 | $205.87 |
| 52 Week High | $665.18 | $495.55 |
| Indicator | MLM | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 32.58 |
| Support Level | $606.56 | $420.30 |
| Resistance Level | $634.57 | $479.79 |
| Average True Range (ATR) | 13.10 | 17.70 |
| MACD | 2.23 | -5.81 |
| Stochastic Oscillator | 75.31 | 10.11 |
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). In 2024, Martin Marietta sold 191 million tons of aggregates. Martin Marietta's most important markets include Texas, North Carolina, Colorado, California, and Georgia, accounting for most of its sales. The company also uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.